Our business is supported by significant market growth and gaps of novel therapies within the ophthalmology space.

Chinese ophthalmic pharmaceutical market has reached USD 3 billion, at a CAGR of 16%. Its growth rate is higher than that of the global market. Currently, there are many generics of sodium hyaluronate, prostaglandins, praprofen eye drops, levofloxacin eye drops and other products. Round 70% of innovative ophthalmic drugs marketed overseas have not been introduced to China. The innovative ophthalmic drugs approved in China are significantly less than those in the United States every year. China, and Southeast Asia, the emerging markets, have significant unmet medical needs for novel ophthalmic drugs.

We seize the opportunities in the emerging ophthalmic medicine markets in China and Southeast Asia through our unique platform and global network.

We are establishing a differentiated ophthalmic medicine portfolio through our unparalleled innovation strategy.